Drugs / MVX-ONCO-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05071846 | Oct 2024 → Nov 2026 expected | cancer | University Hospital, Geneva | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVX-ONCO-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05071846 ↗ |
| Modality | Cell therapy | “patient-specific, cell-based, active immunotherapy” NCT05071846 ↗ |
| Route | Other | “the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells” NCT05071846 ↗ |